Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
Gastroenterol Hepatol
    February 2024
  1. JORQUERA F, Ledesma F, Ahumada A, Manzano ML, et al
    Clinical profile of Spanish hepatitis C virus-infected treatment-naive patients with compensated cirrhosis in the CREST study.
    Gastroenterol Hepatol. 2024 Feb 12:S0210-5705(24)00037.
    >> Share

  2. LIU Y, Chen S, Yu S, Wang J, et al
    LPS-TLR4 pathway exaggerates alcoholic hepatitis via provoking NETs formation.
    Gastroenterol Hepatol. 2024;47:158-169.
    >> Share

    December 2023
  3. CONTHE A, Ahumada A, Gallego Duran R, Marti-Aguado D, et al
    Current dilemmas in hepatitis virus C management. What should we do after achieving sustained virologic response?
    Gastroenterol Hepatol. 2023;46:826-829.
    >> Share

  4. RIVEIRO-BARCIELA M, Roade L, Martinez-Camprecios J, Vidal-Gonzalez J, et al
    mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
    Gastroenterol Hepatol. 2023;46:764-773.
    >> Share

  5. ARZALLUS T, Izagirre A, Castiella A, Torrente S, et al
    Drug induced autoimmune hepatitis after turmeric intake.
    Gastroenterol Hepatol. 2023;46:805-806.
    >> Share

    August 2023
  6. CALLEJA PANERO JL, de la Poza G, Hidalgo L, Aguilera Sancho-Tello MV, et al
    Patient journey of individuals tested for HCV in Spain: LiverTAI, a retrospective analysis of EHRs through natural language processing.
    Gastroenterol Hepatol. 2023;46:491-503.
    >> Share

    April 2023
  7. PEREZ-HERNANDEZ FJ, Morales-Arraez DE, Amaral-Gonzalez C, Gonzalez-Mendez Y, et al
    Asynchronous electronic consultation between primary care and specialized care proved effective for continuum of care for viraemic hepatitis C patients.
    Gastroenterol Hepatol. 2023;46:266-273.
    >> Share

  8. HUANG J, Liu Y, Liu Y
    Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis.
    Gastroenterol Hepatol. 2023;46:309-318.
    >> Share

    February 2023
  9. MARTINEZ RAMIREZ NM, Gonzalez Praetorius A, Martinez Benito Y, Garcia Rivera MV, et al
    Changes in the epidemiology of hepatitis A: Clinical and preventive implications.
    Gastroenterol Hepatol. 2023;46:116-123.
    >> Share

    January 2023
  10. FRAILE-LOPEZ M, Alvarez-Navascues C, Gonzalez-Dieguez ML, Cadahia V, et al
    Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
    Gastroenterol Hepatol. 2023 Jan 27:S0210-5705(23)00013.
    >> Share

  11. NEOKOSMIDIS G, Protopapas AA, Stogiannou D, Filippidis A, et al
    Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C.
    Gastroenterol Hepatol. 2023;46:58-66.
    >> Share

  12. SHARKAWI FZE, El-Sherbiny M, Ali SAM, Nassif WMH, et al
    The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection.
    Gastroenterol Hepatol. 2023;46:17-27.
    >> Share

    December 2022
  13. MARTINEZ-CAMPRECIOS J, Riveiro-Barciela M, Munoz-Gomez R, Londono MC, et al
    [Not Available].
    Gastroenterol Hepatol. 2022 Dec 27:S0210-5705(22)00313.
    >> Share

    November 2022
  14. GARRIDO-ESTEPA M, Herruzo R, Flores-Herrera J
    Co-infections, comorbidities, and alcohol or other substances abuses in chronic hepatitis C-related hospitalisations in Spain.
    Gastroenterol Hepatol. 2022;45:677-689.
    >> Share

    October 2022
  15. CRESPO J, Cabezas J, Aguilera A, Berenguer M, et al
    Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.
    Gastroenterol Hepatol. 2022 Oct 15. pii: S0210-5705(22)00235.
    >> Share

  16. CUNHA-SILVA M, Torres LD, Fernandes MF, Secundo TML, et al
    Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease.
    Gastroenterol Hepatol. 2022;45:579-584.
    >> Share

    August 2022
  17. LAVIN AC, Cabezas J, Crespo J
    Letter to the editor in response to the recently published article "Roncero C, Buch B, Martin-Sanchez AM, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis. Gastroenterol Hepato
    Gastroenterol Hepatol. 2022 Aug 11. pii: S0210-5705(22)00183.
    >> Share

    June 2022
  18. RONCERO C, Buch B, Martin-Sanchez AM, Alvarez-Navares AI, et al
    Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis.
    Gastroenterol Hepatol. 2022 Jun 30. pii: S0210-5705(22)00172.
    >> Share

  19. GUTIERREZ-ROJAS L, de la Gandara Martin JJ, Garcia Buey L, Uriz Otano JI, et al
    Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: results of a literature review.
    Gastroenterol Hepatol. 2022 Jun 16. pii: S0210-5705(22)00164.
    >> Share

    May 2022
  20. ANDRES L, Badia E, Fernandez C, Puebla A, et al
    AUTOIMMUNE HEPATITIS. ANOTHER CONSEQUENCE OF COVID-19?
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00150.
    >> Share

  21. CHEN M, Wu Z, Du Z, Sun S, et al
    Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis.
    Gastroenterol Hepatol. 2022;45:361-372.
    >> Share

    April 2022
  22. TORRENTE S, Castiella A, Garmendia M, Zapata E, et al
    Probable autoimmune hepatitis reactivated after COVID-19 vaccination.
    Gastroenterol Hepatol. 2022;45 Suppl 1:115-116.
    >> Share

  23. MACIA-RODRIGUEZ C, Santome Couto L, Fernandez Villaverde A, Romero Reinoso C, et al
    Mycophenolate mofetil as a treatment of severe steroid-resistant immune-related hepatitis.
    Gastroenterol Hepatol. 2022;45 Suppl 1:32-36.
    >> Share

    March 2022
  24. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    >> Share

  25. PEREZ JIMENEZ RD, Granados Monzon R, Hernandez Febles M, Pena Lopez MJ, et al
    Acute hepatitis due to the hepatitisC virus: Where are the transmission occurring?
    Gastroenterol Hepatol. 2022;45:192-197.
    >> Share

    February 2022
  26. ARANDA EB, Marcos CF, Maestu AP, Marin VG, et al
    EVOLUTION OF HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS CURED WITH DIRECT-ACTING ANTIVIRALS. LONG-TERM FOLLOW-UP.
    Gastroenterol Hepatol. 2022 Feb 18. pii: S0210-5705(22)00064.
    >> Share

  27. RASHIDI A, Sedaghat F, Nejat A, Azarpira N, et al
    Immunity to hepatitis A virus in liver transplant recipients: A population-based study in Iran.
    Gastroenterol Hepatol. 2022;45:99-105.
    >> Share

  28. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    >> Share

    December 2021
  29. OLIVAS I, Cobreros M, Londono MC, Diaz-Gonzalez A, et al
    Budesonide in the first line treatment of patients with autoimmune hepatitis.
    Gastroenterol Hepatol. 2021 Dec 16. pii: S0210-5705(21)00319.
    >> Share

    October 2021
  30. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    >> Share

    September 2021
  31. GARCIA-FRAILE LJ, Garcia-Buey L, Cerezo CA, Sanz JS, et al
    ENGLISH: Evolution of HCV associated Porphyria Cutanea Tarda after HCV Sustained Virologic Response by Direct Acting Antivirals.
    Gastroenterol Hepatol. 2021 Sep 22. pii: S0210-5705(21)00248.
    >> Share

  32. DE CANETE CAMACHO JCF, Martinez AM, Mena MAG, Maria Moreno Planas J, et al
    Influence of psychiatric disorders and opioid substitution therapy on hepatitis c treatment with direct-acting antivirals in people who inject drugs.
    Gastroenterol Hepatol. 2021 Sep 17. pii: S0210-5705(21)00251.
    >> Share

  33. CAMARERO JG, Aranda EB, Castro RQ, Chumillas RMS, et al
    Hepatitis B And C Screening In Hospitalized Patients With Sars-Cov-2 Infection.
    Gastroenterol Hepatol. 2021 Sep 8. pii: S0210-5705(21)00250.
    >> Share

    June 2021
  34. TURNES J, Rincon D, Calleja JL, Delgado MB, et al
    Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naive non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Gastroenterol Hepatol. 2021 Jun 12. pii: S0210-5705(21)00198.
    >> Share

    May 2021
  35. REYGOSA C, Arraez DM, Hernandez-Bustabad A, Baute LM, et al
    Hepatitis C-Treated Patients As A Potential Source For Referral Of New Cases.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00148.
    >> Share

    April 2021
  36. BUSTA NISTAL MR, Garcia Sanchez MC, Mora Cuadrado N, Dura Gil M, et al
    Cholestatic hepatitis as a presentation of secondary syphilis.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00117.
    >> Share

  37. COSTA CA, Garcia JLR, Gandia MAR, Martos RF, et al
    FULMINANT LIVER FAILURE DUE TO HEPATITIS B REACTIVATION DURING THE COVID-19 PANDEMIC.
    Gastroenterol Hepatol. 2021 Apr 13. pii: S0210-5705(21)00118.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016